Response and remission rates after 5 weeks of treatment in 40 depressed patients (sample 2) treated with either reboxetine (n = 20) or mirtazapine (n = 20) [33]. Patients are subdivided into COR peak

NIAID Data Ecosystem50

Quality health indicators achieved over the first 12 months of observation, stratified by treatment allocation (N = 818).

临床疗效评估

医疗质量指标

Quality health indicators achieved over the first 12 months of observation, stratified by treatment allocation (N = 818).

Figshare2022-11-02 更新30

Overview of included RRMS phase-3 trials (n = 13).

多发性硬化症临床试验

临床疗效评估

RRF = Rate of relapse free patients after 2 years, SE = Standard error, ARR = Annualized relapse rate over 2 years, SD = Standard deviation, 2001/2005 indicates the use of the original 2001 McDonald c

Figshare2015-12-02 更新50

Supplementary Material for: A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression

肿瘤免疫治疗

临床疗效评估

Introduction: In a multicenter, open-label, parallel-group, randomized, phase 2 study for pretreated advanced hepatocellular carcinoma (HCC), camrelizumab showed potent antitumor activity and acceptab

NIAID Data Ecosystem50

Comparison of baseline characteristics between responder and non-responder.

资源简介：

相关数据集